Sana Biotechnology
Sana Biotechnology develops engineered cell and gene therapies to repair, control, or replace cells in order to address the underlying causes of diseases such as diabetes, B-cell cancers, and B-cell related autoimmune disorders. Its mission is to create novel medicines that meaningfully improve patient outcomes and broaden access to transformative treatments.
Facts
- Sectors
- Biotechnology, Gene editing, Cell therapy, Biopharmaceuticals
- Founded
- 2018 Seattle business license
- Type
- Corporation Seattle business license
- Registered name
- Sana Biotechnology Inc Seattle business license
- Stage
- Public
- Members see funding amounts. .
Is this your organization? Claim it
GeekWire Summit: Sana CEO reveals details about stealthy gene therapy startup
Founded by veterans of Juno Therapeutics, Sana Biotechnology is developing new ways to modify genes and replace damaged cells in the body, possibly pioneering new treatments for a number of diseases. Sana CEO Steve Harr shed more light on one of most secretive, heavily funded startups in Seattle and the global biotech industry during this fireside chat at the GeekWire Summit. Originally shown October 22, 2020. Moderated by Luke Timmerman, The Timmerman Report.
People
-
Steve Harr Co-founder and President and Chief Executive Officer
-
Snehal Patel Executive, Executive Vice President and Chief Technical Officer